Literature DB >> 12355096

A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes.

Marielle Cavrois1, Carlos De Noronha, Warner C Greene.   

Abstract

As an early event in the viral life cycle, the entry of enveloped viruses into target cells has received considerable attention. Viral fusion to cellular targets has been studied principally with fusion assays in which cells engineered to express the viral envelope are cultured with the target cells. These assays yield valuable information but do not fully recapitulate all of the variables governing the fusion of actual virions to their cellular targets. The virion membrane and the plasma membrane, for example, differ strikingly in their lipid and protein compositions. Two virion-based fusion assays have been described. One is based on the redistribution of a self-quenching fluorophore, whereas the second depends on photosensitized activation of a hydrophobic probe by a fluorescent lipid loaded into the target membrane. These assays are complex and have not been adapted to study fusion in complex cell populations. We have developed a simple, rapid assay allowing the detection of HIV-1 virion fusion to biologically relevant target cells, including primary CD4(+) T lymphocytes. It is based on the incorporation of beta-lactamase-Vpr chimeric proteins (BlaM-Vpr) into HIV-1 virions and their subsequent delivery into the cytoplasm of target cells as a result of virion fusion. This transfer is then detected by enzymatic cleavage of the CCF2 dye, a fluorescent substrate of beta-lactamase (BlaM), loaded in the target cells. BlaM cleaves the beta-lactam ring in CCF2, changing its fluorescence emission spectrum from green (520 nm) to blue (447 nm) and thereby allowing fusion to be detected by fluorescence microscopy, flow cytometry, or UV photometry.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355096     DOI: 10.1038/nbt745

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  302 in total

1.  Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection.

Authors:  Graham Simmons; Andrew J Rennekamp; Ning Chai; Luk H Vandenberghe; James L Riley; Paul Bates
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes.

Authors:  Evelyne Schaeffer; Vanessa B Soros; Warner C Greene
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  Rapid and sensitive detection of retrovirus entry by using a novel luciferase-based content-mixing assay.

Authors:  Andrey A Kolokoltsov; Robert A Davey
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

4.  Naturally occurring fragments from two distinct regions of the prostatic acid phosphatase form amyloidogenic enhancers of HIV infection.

Authors:  Franziska Arnold; Jacqueline Schnell; Onofrio Zirafi; Christina Stürzel; Christoph Meier; Tanja Weil; Ludger Ständker; Wolf-Georg Forssmann; Nadia R Roan; Warner C Greene; Frank Kirchhoff; Jan Münch
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

5.  Protein transduction from retroviral Gag precursors.

Authors:  Christine Voelkel; Melanie Galla; Tobias Maetzig; Eva Warlich; Johannes Kuehle; Daniela Zychlinski; Juergen Bode; Tobias Cantz; Axel Schambach; Christopher Baum
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

6.  Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant.

Authors:  Chisu Song; Christopher Aiken
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

7.  Ceramide, a target for antiretroviral therapy.

Authors:  Catherine M Finnegan; Satinder S Rawat; Anu Puri; Ji Ming Wang; Francis W Ruscetti; Robert Blumenthal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

8.  Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells.

Authors:  Minoru Tobiume; Janet E Lineberger; Christopher A Lundquist; Michael D Miller; Christopher Aiken
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  The V4 and V5 Variable Loops of HIV-1 Envelope Glycoprotein Are Tolerant to Insertion of Green Fluorescent Protein and Are Useful Targets for Labeling.

Authors:  Shuhei Nakane; Aikichi Iwamoto; Zene Matsuda
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

10.  Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection.

Authors:  David Y-W Lee; Xudong Lin; Elena E Paskaleva; Yanze Liu; Shadakshara S Puttamadappa; Carol Thornber; James R Drake; Maja Habulin; Alexander Shekhtman; Mario Canki
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.